Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice

Cancer Gene Therapy

Volumn 17, Issue 4, 2010, Pages 275-288

  Zhang, R ^a   Ma, L ^a,b   Zheng, M ^a   Ren, J ^a   Wang, T ^a   Meng, Y ^a   Zhao, J ^a   Jia, L ^a   Yao, L ^a   Han, H ^a   Li, K ^b   Yang, A ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; HCC; ShRNA; Survivin

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; ETOPOSIDE; SHORT HAIRPIN RNA; SURVIVIN; SURVIVIN SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LIVER NEOPLASMS, EXPERIMENTAL; LUCIFERASES; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 77949659596     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.68     Document Type: Article

References (42)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
2. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182.
3. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
4. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
5. Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002; 109: 285-286.
6. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 162-171.
7. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108: 981-990.
8. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-1081.
9. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT. Suppression of survivin expression inhibits in vivo tumor-igenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63: 7724-7732.
10. Sun Y, Lin R, Dai J, Jin D, Wang SQ. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 2006; 16: 365-374.
11. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
13. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351: 1772-1777.
14. Tang ZY. Hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15(Suppl): G1-G7.
15. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-1085.
16. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000; 19: 1346-1353.
17. Wu L, Wang Y, Tian D. Knockdown of survivin expression by siRNA induces apoptosis of hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 403-406.
18. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
19. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200.
20. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63: 3593-3597.
21. Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H et al. Use of adeno-virusdelivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-2041.
22. Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 2006; 43: 1042-1052.
23. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
24. Liu J, Du W, Fan D. Survivin, the promising target in hepatocellular carcinoma gene therapy. Cancer Biol Ther 2008; 7: 555-556.
25. Zhu DE, Hoti N, Song Z, Jin L, Wu Z, Wu Q et al. Suppression of tumor growth using a recombinant adenovir-al vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model. Cancer Gene Ther 2006; 13: 762-770.
26. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13: 385-393.
27. Bertrand JR, Pottier M, Vekris A. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296: 1000-1004.
28. Kumar R, Conklin DS, Mittal V. High-Throughput Selection of Effective RNAi Probes for Gene silencing. Genome Res 2003; 13: 2333-2340.
29. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
30. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells\a mechanism of immune evasion? Nat Med 1996; 2: 1361-1366.
31. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-939.
32. Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y et al. Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 1999; 30: 920-926.
33. Fei Q, Zhang H, Fu L, Dai X, Gao B, Ni M et al. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Acta Biochim Biophys Sin 2008; 40: 466-477.
34. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y et al. Targeting X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand-and chemotherapeutic agent-induced cell death. Oncol Rep 2005; 14: 1311-1316.
35. He SQ, Rehman H, Gong MG, Zhao YZ, Huang ZY, Li CH et al. Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellu-lar carcinoma via cell cycle arrest. Cancer Biol Ther 2007; 46: 1247-1257.
36. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
37. Dummer R, Rochlitz C, Velu T, Acres B, Limacher JM, Bleuzen P et al. Intralesional adenovirus-mediated inter-leukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008; 16: 985-994.
38. Shen C, Buck AK, Liu X, Winkler M, Reske SN. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003; 539: 111-114.
39. Verma IM, Somia N. Gene therapy\promises, problems and prospects. Nature 1997; 389: 239-242.
40. Vile R. Cancer gene therapy\new approaches to tumour cell killing. J Gene Med 2000; 2: 141-143.
41. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4: 403-409.
42. Kay MA, Graham F, Leland F, Woo SL. Therapeutic serum concentration of human alpha-1-antitrypsin after adenoviral mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815-819.